LFM A13, BTK kinase inhibitor
-
Catalog number
SIH-461-25MG
-
Price
Please ask
-
Size
25 mg
-
-
Stock availabilitIn Stock
In Stock
-
CAS number
62004-35-7
-
Description
BTK kinase inhibitor
-
Molecular weight
360 g/mol
-
Primary research fields
Cell Signaling, Cancer, Apoptosis, Cancer Growth Inhibitors, Tyrosine Kinase Inhibitors
-
Other name
2-Cyano-N-(2,5-dibromophenyl)-3-hydroxy-2-butenamide
-
Product category
Small Molecules
-
Product type
Inhibitor
-
Chemical formula
C11H8Br2N2O2
-
Origin
Synthetic
-
Purity pourcentage
≥97% (TLC)
-
Soluble in
Soluble in DMSO (10 mg/ml) or ethanol (0.3 mg/ml)
-
Physical appearance
Yellow solid
-
Storage recommendations
-20ºC
-
Shipping recommendations
Shipped Ambient
-
Safety information
Classification: Not a hazardous substance or mixture. Safety Phrases: S22 - Do not breathe dust. S24/25 - Avoid contact with skin and eyes. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection.
-
PubChem number
54686938
-
Scientific context
LFM A13 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK).
-
Bibliography
1. Vassilev A., Ozer Z., Navara C., Mahajan S., & Uckun F.M. (1999). J. Biol. Chem. 274(3): 1646–1656.
-
Release date
1-Oct-2014
-
PubMed number
Refer to PubMed
-
Tested applications
To be tested
-
Tested reactivity
To be tested
-
-
Representative figure legend
Chemical structure of LFM A13 (SIH-461), a BTK kinase inhibitor. CAS #: 62004-35-7. Molecular Formula: C11H8Br2N2O2. Molecular Weight: 360 g/mol. Chemical structure of LFM A13, a BTK kinase inhibitor (SIH-461). CAS # 62004-35-7. Molecular Formula: C11H8Br2N2O2.
-
Warning information
Non-hazardous
-
Country of production
Canada
-
Total weight kg
0.25
-
Net weight g
0.025
-
-
Additional description
Tissue, pathway, proteinase, peptidase, protease ,acrosin, lipoprotein, activator, caspase, trypsin, papain, esterase inhibitors are proteins or receptor ligands or receptor antagonists that bind to an enzyme receptor and decreases its activity. Since blocking an enzyme's activity can kill a pathogen or correct a metabolic imbalance, many drugs are enzyme inhibitors. Not all receptor antagonist that bind to enzymes are inhibitors; enzyme activator ligands or agonists bind to enzymes and increase their enzymatic activity, while enzyme substrates bind and are converted to products in the normal catalytic cycle of the enzyme.
-
Gene target
-
Gene symbol
SNAR-A13, BTK
-
Short name
LFM A13, BTK kinase inhibitor
-
Alternative name
LFM A13, Bruton agammaglobulinemia tyrosine kinase phosphorylation catalyst suppressor
-
Alternative to gene target
Bruton agammaglobulinemia tyrosine kinase, AGMX1 and AT and ATK and BPK and IMD1 and PSCTK1 and XLA, BTK and IDBG-79651 and ENSG00000010671 and 695, phosphatidylinositol-3, nuclei, Btk and IDBG-171427 and ENSMUSG00000031264 and 12229, BTK and IDBG-633447 and ENSBTAG00000019250 and 533459
-
Gene info
Gene info
-
Identity
-
Gene
-
Long gene name
Bruton tyrosine kinase
-
Synonyms gene
-
Synonyms gene name
- Bruton agammaglobulinemia tyrosine kinase
-
Synonyms
-
Synonyms name
-
GenBank acession
-
Locus
-
Discovery year
1986-01-01
-
Entrez gene record
-
Pubmed identfication
-
RefSeq identity
-
Classification
- Tec family tyrosine kinases
- SH2 domain containing
- Pleckstrin homology domain containing
-
VEGA ID
-
Locus Specific Databases
Similar products
